Southern Research’s Post

Everyone is talking about the German biotech financing gap, but are you aware of the many success stories written by the sector?   German biotech companies not only grew significantly across key industry metrics but also capture the global spotlight with their innovative power: ·        Strong growth in number of employees and R&D expenses ·        Revenues and market capitalization pointing upward over the long term ·        Biotech drug developers expanding their therapeutic pipelines ·        Alliances "biobucks" on high level (€11.4 billion) ·        Large-volume M&A deals in the first quarter of 2024 (€5.0 billion)   Furthermore, I am deeply impressed by Germany's biotech innovators who are leading the charge with breakthroughs in: ·        Next-generation radiopharmaceuticals ·        Microbiome-based therapeutics ·        Cutting-edge gene and cell therapies ·        Smart biotech materials ·        Revolutionary novel foods ·        And last but certainly not least, AI-powered solutions throughout various biotech application areas Dive into our German Biotechnology Report 2024 for an in-depth look at these success stories and more – of course we also analyze the German biotech financing gap: https://lnkd.in/egnQsNa4   What are the biotech achievements that inspire you the most? Share them in the comments!        #EYBiotech #BioDeutschland #Biotechnologie

America’s biotechnology sector is the envy of the world, at least for the time being. It develops about two-thirds of all new medicines invented worldwide.  U.S.-invented COVID vaccines helped end the pandemic, and important new applications of the mRNA technology behind those vaccines are on the horizon. Innovations in oncology have driven cancer death rates down by 33 percent — saving an estimated 3.8 million lives. And we’re on the verge of important breakthroughs with revolutionary new medicines that have been shown to slow the progression of Alzheimer’s disease. Medical advances have been so swift and dramatic that some scientists are calling our era a “golden age for medicine.” https://lnkd.in/ggPWhS7Q

💡New light on the horizons of Biopharma and Biotechnology! Our in-depth feature on 100XBIO will take you along on their innovative journey of revolutionizing T cell research. Based in Woburn, Massachusetts, their incredible startup is focused on amplifying data on antigen specificity of the T cells, thus paving the way for significant breakthroughs in life science. Their approach could be the very future we needed in our race against numerous health challenges. A shout-out to the relentless work of founders Sergei Pustylnikov, Ph.D. and Sofya Leyn, PhD, who are driving the force behind the unmatched efficiency of 100XBIO. Let's break down the barriers of conventional research and see what the future brings! https://lnkd.in/e8BXw6xb Stay innovative, stay inspired, and above all, stay hopeful. 🌟 #Biopharma #Biotechnology #LifeScience #Innovation #Startup #FutureTech #USVentureNews 

🔬 Exploring Preclinical Assets Market Dynamics 🔬 The preclinical assets market is experiencing robust growth, with projections from $5.32 billion in 2023 to $5.83 billion in 2024, demonstrating a compound annual growth rate (CAGR) of 9.7%. Key drivers include evolving drug development needs, biotechnology advancements, and collaborative research efforts. Looking ahead, forecasts predict continued growth, reaching $8.34 billion by 2028, fueled by precision medicine, AI integration, and a focus on rare diseases. Discover more insights in the Preclinical Assets Market Report 2024. 🌟 Embracing Innovation: Major Trends Ahead 🌟 Anticipate emerging trends: Advanced imaging techniques Utilization of 3D organoid models Integration of multi-omics data Automation and high-throughput screening Increased drug discovery efforts are driving market growth, with preclinical assets playing a pivotal role in selecting clinical candidates. 💡 Product Innovation: A Key Driver 💡 Companies like Charles River Laboratories and Valo Health are innovating new products, such as Logica, an AI-powered drug solution. This translates biological insights into optimized preclinical assets. https://lnkd.in/g9ntBBmg In conclusion, the preclinical assets market is primed for significant expansion. As precision medicine and AI reshape drug discovery, stakeholders must embrace emerging trends for sustained success. #tbrc #preclinical #healthcare #marketsize #marketoverview #Biotech #DrugDiscovery

Poland is emerging as a biotech hub, with eight companies at the forefront, innovating in biologics and technologies for critical health issues. As these pioneers redefine the landscape, what opportunities does this create for global health advancements and entrepreneurial ventures in biotech?

I’m thrilled to announce that Lactocore Group is actively seeking a seed investment round for our innovative Reptide platform, which is set to revolutionize the field of biotechnology with AI-enhanced peptide drugs. Regulatory peptides are not just the most abundant class of signaling molecules in our bodies; they are also among the most successful types of drugs on the market today. At Lactocore, we are pushing the boundaries of this success further by harnessing cutting-edge solutions in structural bioinformatics and artificial intelligence. Our proprietary technology — comprising a proprietary dataset and spiking neural network architecture — enables us to explore new chemical spaces for proven pharmaceutical targets. We have developed a robust pipeline of peptide drug candidates tailored for psychiatric and metabolic disorders. Our leading program, aimed at treating anxiety, is prepared for IND/CTA-enabling studies. In addition, we are advancing promising assets in neurological disorders, diabetes, and cardiovascular diseases. This seed round represents a remarkable opportunity for early-stage investors to join us on a transformational journey in the pharmaceutical industry. We are looking for partners who share our vision and commitment to innovate and deliver groundbreaking treatments that can significantly improve patient outcomes. Interested in learning more about how you can participate in our growth story? Please reach out directly to discuss how we might collaborate on this exciting venture. #Biotechnology #StartUpInvesting #HealthTech #AI #Pharmaceuticals #InvestmentOpportunity #MentalHealthAwareness #Innovation #LifeSciences #PeptideTherapy

The biotech market continues to be a tale of two cities. Empty labs sit alongside a record-breaking number of FDA approvals. Some companies are thriving while others (especially cash-strapped companies with early stage assets) are not. Despite the challenges, the surge in FDA approvals, obesity drug development and a robust wave of late-stage approvals are factors pointing toward promising future, noted Travis McCready, head of life sciences, Americas markets at JLL, in an insightful interview. #biotech #lifesciences #venturecapital https://lnkd.in/gZwsbj3f

🚀 Exciting Update! Our startup is in the development phase, crafting innovative bioinformatics and AI solutions for RNA-based therapies. Currently, we're focusing on harnessing plant-origin microRNAs to tackle various diseases. 🔍 We need your valuable input! Please take a moment to complete and share our survey within your network. Your feedback, especially from experts in pharmaceuticals and biotechnology, will shape our future endeavors. Survey Link: https://lnkd.in/dXdyA9tr Thank you for your support! For any questions or suggestions, feel free to reach out directly. #Bioinformatics #AI #RNAtherapies #MarketResearch #HealthcareInnovation #Pharma #Biotech #StartupJourney #innovation #pharma #RNA #MyRNAPP #Startup #tech #PMR

Throwback - #snwlabs goes FACTORY+ In November 2023, Small New World was added to the FACTORY+ INCUBATION PROGRAM! The FACTORY is Startup Salzburg's incubation program, which supports innovative, market- and startup-ready Salzburg startups every year. Startup Salzburg supports startups in their individual development, connects startuper with mentors and cooperation partners from the established economy and much more. The new additional program FACTORY+ (AplusB https://lnkd.in/daps3_x5) particularly promotes research, technology and innovation-based start-up projects and supports them with special additional services. https://lnkd.in/gc5-nzRN Small New World Laboratories, a PMU spin-off, which emerged from the GMP laboratory, produces vesicle-containing pharmaceutical preparations derived from stem cells. This means that new forms of intervention and therapy can be offered for the first time, such as for spinal cord injuries or the insertion of cochlear implants for deafness. The GMP laboratory (Good Manufacturing Practice Laboratory) is one of the few academic-pharmaceutical institutions in the world that can produce vesicles for administration to humans. Vesicles have an important communication function in the body and transmit targeted information between cells, organs and even between different organisms. That is why their role in regenerative medicine is considered very promising. #nanovesiculartechnology #efre #evttsalzburg #extracellularvesicles #exosomes #nanovesiculartherapy #atmps #biologicals #theralytics #frombenchtobedside #salzburg #research #science #gmp #manufacturing #pharma #innovation #regenerativemedicine #genetherapy #celltherapy #biologics #atmp

It is a 'Tale of Two Cities' indeed. But the signs look promising! @Biotechs Early Development, Market Monitoring, Market Insights and Product Planning professionals....What is your strategy? DM me for your strategy and decision support today! #Biotech #Innovation #DrugDevelopment #DrugDiscoveryTrends #ForwardLooking